Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB
NCT07579910Phase 3Not yet recruiting
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Dec 2026
- Primary completion
- Aug 2033
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
01
Overview
A Phase 3 trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Spruce Biosciences, Inc.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT07579910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07579910.